Key Takeaways:
Fusen Pharmaceutical Co., Ltd. (1652.HK) has received marketing approval from China's National Medical Products Administration for its Lornoxicam for Injection, a treatment for acute moderate pain after surgery, sending its shares up nearly 6 percent.
"The launch of Lornoxicam for Injection adds an important new product to Fusen’s portfolio and strengthens its presence in China’s hospital-based pain management market," the company said in a statement regarding the approval.
Developed by Fusen's wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, the drug is a non-steroidal, non-opioid analgesic. It offers pain relief comparable to morphine but with fewer side effects and a lower risk of addiction, according to a company announcement. The drug is already included in China's national reimbursement system as a Class B drug.
The approval positions Fusen to compete in China's domestic hospital market for perioperative analgesia, where sales of similar injection products exceeded 300 million yuan in 2025. By providing a safer alternative to opioid-based painkillers, Lornoxicam aligns with current clinical guidelines favoring multimodal pain management strategies.
The approval provides a significant catalyst for Fusen, opening a new revenue stream in a sizable market. Investors will now watch for initial sales data in the coming quarters to gauge market uptake and the drug's impact on the company's earnings.
This article is for informational purposes only and does not constitute investment advice.
